Session: 101. Red Cells and Erythropoiesis, Excluding Iron: Poster I
Hematology Disease Topics & Pathways:
Research, Diseases, Biological Processes
We present here a patient with compound heterozygous pathogenic variants in ATG5, leading to severe ATG5 protein deficiency, associated with syndromic congenital dyserythropoietic anemia, phenocopied in ex vivo erythropoiesis cultures using Bristol Erythroid Adult Line 2 (BEL-A2) cells after CRISPR-Cas9 mediated deletion of ATG5.
A 4-month old male infant with transfusion-dependent anemia and signs of dyserythropoiesis since birth was enrolled in the Congenital Dyserythropoietic Anemia (CDA) Registry of North America (NCT02964494). He was born prematurely after 32 weeks gestation, complicated by intrauterine growth retardation and prenatal hydrops fetalis. His phenotype after delivery included respiratory failure, hepatosplenomegaly, and severe functional and anatomic neurological features (seizure disorder, lissencephaly, hypogenesis of the corpus callosum and a hypoplastic vermis). He remained in intensive care, with no improvement until death at 5 months of age, attributable to panlobular acute necrotizing bronchopneumonia superimposed on severe bronchopulmonary dysplasia, with CDA, adrenal insufficiency, and neurodevelopmental abnormalities.
Microarray analysis detected a maternally inherited interstitial deletion of 1.8 Mb of DNA from the long arm of chromosome 6 (6q21), encompassing fully ATG5, QRSL1, RTN4IP1 and the final exon of PDSS2, all associated with autosomal recessive Mendelian diseases. Whole Genome Sequencing (WGS) of the proband and parents with trio-analysis revealed a paternally-inherited splicing variant in ATG5 (c.236+1G>T) which appeared homozygous due to the complete deletion of the gene in trans. Western blot of cell lysate from cultured patient-derived fibroblasts confirmed complete absence of ATG5 as well as of LC3-II. We have performed CRISPR/Cas9-mediated ATG5 deletion in the BEL-A2 cell line. Differentiation of BEL-A2 ATG5-knock-out (ko) clones versus control demonstrated that ATG5 loss did not significantly affect the rate of erythroblast differentiation or survival but did cause dyserythropoiesis with binucleation and nuclear atypia, progressively worsening with maturation. Most importantly, impaired mitophagy was noted in the stage of orthochromatic erythroblasts, with mitochondria still present in ATG5-ko red cells after enucleation. Studies utilizing patient and healthy control-derived induced pluripotent stem cells (iPSCs) are ongoing to further evaluate the role of ATG5 in another model of human erythropoiesis in vitro.
This case and the associated in vitro studies demonstrate that ATG5 is indispensable for terminal erythropoiesis in humans in contrast to the finding on murine studies that ATG7 is more essential to red cell development, providing another example of differences between murine and human erythropoiesis.
Disclosures: Lutzko: Elixirgen Therapeutics, Inc: Research Funding. Kalfa: Agios Pharmaceuticals: Research Funding; Novo Nordisk: Research Funding.
See more of: Oral and Poster Abstracts